Bioscript
Bioscript is a successful medical communications and regulatory writing agency for pharmaceutical companies
Sector
Healthcare and life sciences
Status
Current
Investment Date
2021
Location
UK, Germany and US
Buy & Build
4
Investment background
Sovereign invested in Bioscript in 2021, partnering with the founder and management team to accelerate the growth of a high‑science commercialisation services platform. Established in 2005, Bioscript had built a strong reputation for medical communications, regulatory writing and scientific consultancy, underpinned by deep therapeutic expertise in oncology, immunology and rare disease.
Sovereign identified a clear opportunity to scale the group through selective acquisitions, broaden its specialist service lines, and bolster its management team to support the next stage of growth.
The story so far
Four acquisitions completed, expanding scale and capabilityHigh‑science workforce with deep expertiseStrong organic growthData Insights and AI adoption driving efficiencySince backing the business, Sovereign and the leadership team have transformed Bioscript into a significantly larger, more diversified scientific communications group. Four acquisitions - Fortis, Valid Insight, Meridian and Enzyme Communications - have expanded the business across medical affairs strategy, global market access and high‑science medical communications, while adding depth in key therapy areas and new client relationships.
The investment also enabled a planned succession programme and the development of the group’s central operations, creating an integrated platform capable of winning and delivering larger, more complex global programmes. Bioscript has invested significantly in its leadership with the appointment of a new CEO, CFO, CIO and CPO, as well as divisional Managing Directors.
The company has continued to build momentum through 2025, supported by strong demand for high‑science communications, the expansion of its award‑winning Data Insights division, and a healthy pipeline of further bolt‑on opportunities.
Today, Bioscript partners with 11 of the top 20 global pharma companies, supporting more than 30 launches a year and acting as a trusted partner for scientific content, regulatory documentation, market access strategy and data‑driven insight.
The Sovereign team
We are thrilled to share our journey with Sovereign. They have deep sector expertise and an ability to enhance our growth journey through insightful M&A support and value creation strategies. We feel the partnership has added considerable acceleration to the development of our global scientific communications platform.
